60 related articles for article (PubMed ID: 6616495)
1. Management of patients with metastatic adenocarcinoma of unknown origin: a Southwest Oncology Group study.
Shildt RA; Kennedy PS; Chen TT; Athens JW; O'Bryan RM; Balcerzak SP
Cancer Treat Rep; 1983 Jan; 67(1):77-9. PubMed ID: 6616495
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial.
Buzdar AU; Singletary SE; Valero V; Booser DJ; Ibrahim NK; Rahman Z; Theriault RL; Walters R; Rivera E; Smith TL; Holmes FA; Hoy E; Frye DK; Manuel N; Kau SW; McNeese MD; Strom E; Thomas E; Hunt K; Ames F; Berry D; Hortobagyi GN
Clin Cancer Res; 2002 May; 8(5):1073-9. PubMed ID: 12006521
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of 5-fluorouracil, doxorubicin, and mitomycin C for metastatic small bowel adenocarcinoma.
Gibson MK; Holcroft CA; Kvols LK; Haller D
Oncologist; 2005 Feb; 10(2):132-7. PubMed ID: 15709215
[TBL] [Abstract][Full Text] [Related]
4. Combined nonsimultaneous radiation therapy and chemotherapy with 5-FU, doxorubicin, and mitomycin for residual localized gastric adenocarcinoma: a Southwest Oncology Group pilot study.
Haas CD; Mansfield CM; Leichman LP; Considine B; Bukowski RM
Cancer Treat Rep; 1983 May; 67(5):421-4. PubMed ID: 6687837
[No Abstract] [Full Text] [Related]
5. A prospective, randomized Phase III trial comparing combination chemotherapy with cyclophosphamide, doxorubicin, and 5-fluorouracil with vinorelbine plus doxorubicin in the treatment of advanced breast carcinoma.
Blajman C; Balbiani L; Block J; Coppola F; Chacon R; Fein L; Bonicatto S; Alvarez A; Schmilovich A; Delgado FM
Cancer; 1999 Mar; 85(5):1091-7. PubMed ID: 10091793
[TBL] [Abstract][Full Text] [Related]
6. Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre.
Bontenbal M; Creemers GJ; Braun HJ; de Boer AC; Janssen JT; Leys RB; Ruit JB; Goey SH; van der Velden PC; Kerkhofs LG; Schothorst KL; Schmitz PI; Bokma HJ; Verweij J; Seynaeve C;
J Clin Oncol; 2005 Oct; 23(28):7081-8. PubMed ID: 16192591
[TBL] [Abstract][Full Text] [Related]
7. Combination chemotherapy in the treatment of adenocarcinoma of unknown primary origin.
Walach N; Horn Y
Cancer Treat Rep; 1987 Jun; 71(6):605-7. PubMed ID: 3581098
[TBL] [Abstract][Full Text] [Related]
8. Metastatic adenocarcinomas of unknown primary site: a randomized study of two combination-chemotherapy regimens.
Woods RL; Fox RM; Tattersall MH; Levi JA; Brodie GN
N Engl J Med; 1980 Jul; 303(2):87-9. PubMed ID: 6991941
[No Abstract] [Full Text] [Related]
9. Randomized trial of hexamethylmelamine versus 5-FU, doxorubicin, and cyclophosphamide (FAC) in advanced transitional cell bladder carcinoma: a Southwest Oncology Group study.
Gagliano RG; Stephens RL; Costanzi JJ; Oishi N; Stuckey WJ; Grozea PN; Frank J; Crawford ED
Cancer Treat Rep; 1984; 68(7-8):1025-6. PubMed ID: 6430559
[No Abstract] [Full Text] [Related]
10. Phase I--II study of the combination of 5-FU, doxorubicin, mitomycin, and semustine (FAMMe) in the treatment of adenocarcinoma of the stomach, gastroesophageal junction, and pancreas.
Karlin DA; Stroehlein JR; Bennetts RW; Jones RD; Heifetz LJ; Mahal PS
Cancer Treat Rep; 1982 Aug; 66(8):1613-7. PubMed ID: 7105051
[TBL] [Abstract][Full Text] [Related]
11. Phase I--II evaluation of combination cyclophosphamide, 5-fluorouracil, hexamethylmelamine, and prednisone in advanced breast cancer.
Chang YC; Falkson G; Tormey DC; Crowley J
Cancer Clin Trials; 1981; 4(4):377-80. PubMed ID: 6797746
[TBL] [Abstract][Full Text] [Related]
12. First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial).
Viens P; Palangié T; Janvier M; Fabbro M; Roché H; Delozier T; Labat JP; Linassier C; Audhuy B; Feuilhade F; Costa B; Delva R; Cure H; Rousseau F; Guillot A; Mousseau M; Ferrero JM; Bardou VJ; Jacquemier J; Pouillart P
Br J Cancer; 1999 Oct; 81(3):449-56. PubMed ID: 10507769
[TBL] [Abstract][Full Text] [Related]
13. Combination chemotherapy with cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in advanced breast carcinoma.
Dalley DN; Levi JA; Aroney RS
Med J Aust; 1980 Mar; 1(5):216-8. PubMed ID: 6990214
[TBL] [Abstract][Full Text] [Related]
14. Doxorubicin and cyclophosphamide chemotherapy for disseminated endometrial cancer.
Seski JC; Edwards CL; Gershenson DM; Copeland LJ
Obstet Gynecol; 1981 Jul; 58(1):88-91. PubMed ID: 7195533
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma.
Machiavelli MR; Romero AO; Pérez JE; Lacava JA; Domínguez ME; Rodríguez R; Barbieri MR; Romero Acuña LA; Romero Acuña JM; Langhi MJ; Amato S; Ortiz EH; Vallejo CT; Leone BA
Cancer J Sci Am; 1998; 4(2):125-31. PubMed ID: 9554929
[TBL] [Abstract][Full Text] [Related]
16. Lack of clinical therapeutic synergism between cyclophosphamide, adriamycin, and cis-dichlorodiammineplatinum(II) in metastatic human colorectal carcinoma.
O'Connell MJ; Moertel CG; Rubin J; Schutt AJ; Creagan ET
Cancer Treat Rep; 1980; 64(2-3):311-3. PubMed ID: 7190870
[TBL] [Abstract][Full Text] [Related]
17. Randomized comparison of two combination chemotherapy regimens containing doxorubicin in patients with metastatic breast cancer: a Western Cancer Study Group trial.
Irwin LE; Chlebowski RT; Weiner JM; Reynolds R; Pugh RP; Ryden VM; Bateman JR
Cancer Treat Rep; 1980; 64(8-9):981-4. PubMed ID: 7004635
[TBL] [Abstract][Full Text] [Related]
18. Effect of different neoadjuvant chemotherapy regimens on locally advanced breast cancer.
Coskun U; Gunel N; Onuk E; Yilmaz E; Bayram O; Yamac D; Cihan A; Ucan B; Yildirim Y; Celenkoglu G; Ozkan S
Neoplasma; 2003; 50(3):210-6. PubMed ID: 12937855
[TBL] [Abstract][Full Text] [Related]
19. [Ovarian adenocarcinoma stage III and IV treated by a combination of adriamycin, cyclophosphamide, 5-fluorouracil and cis-DDP. Therapeutic role of cis-DDP in this combination].
Pouillart P; Bretaudeau B; Palangie T; Jouve M; Garcia-Giralt E; Asselain B
Bull Cancer; 1982; 69(5):434-42. PubMed ID: 6891903
[TBL] [Abstract][Full Text] [Related]
20. [Risk of cardiotoxicity of combination treatment radiotherapy and chemotherapy of locally advanced breast carcinoma stage III].
Bustová I
Klin Onkol; 2009; 22(1):17-21. PubMed ID: 19534435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]